A Phase II Study Of SU011248 In Patients With Metastatic Colorectal Cancer Who Have Previously Failed Treatment With Irinotecan, Oxaliplatin, And A Fluoropyrimidine, With And Without Bevacizumab
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Anti-tumor efficacy
Pfizer CT.gov Call Center
Study Director
Pfizer
United States: Food and Drug Administration
A6181003
NCT00077987
December 2003
April 2005
Name | Location |
---|